Day 1 :
Alexandria University, Egypt
Time : 10:00-10:40
Acting Dean of Faculty of Veterinary Medicine, Alexandria University, Matrouh Branch.
This study was aimed to investigate the prevalence toxigenic fungi and mycotoxines, a total no. of 90 samples representing various types of animal and poultry feedstuffs were collected from different localities in Egypt; Alexandria, Beheira, New Valley, Assiut and Cairo, The results showed that 78 with a percentage of 86.7% of samples were contaminated with different fungal species, the fungal load was ranged from 0.4 to 12 x 10³ cfu/gram among different samples, Aspergillus was the most common genus being isolated from all mycologically positive samples with total count of 101900 colonies per gram matching 83.84% of total fungal population. 16 species of Aspergillus; which A. flavus and A. niger were the most common colonizing 72.2% and 56.6% of samples matching 15.8% and 41.7% of total fungal count. Penicillium appeared in 50% of samples accounting for 13.1% of total fungal population. Also in the present study 13 feedstuff samples were analyzed for mycotoxin contamination. These samples were mycologically positive yielding low (40-600 cfu/g) or high number of fungal colonies (1280-4920 cfu/g). A. flavus and A. niger were the dominant species in these samples, aflatoxin B1 at level of 0.851 and 1.363 ug/kg were detected in 2 samples; respectively. Aflatoxin B2 at a level of 0.479 ug/kg was also detected in 1 sample. Levels of Aflatoxins in the positive samples (AFB1 and AFB2) are below the recommended limit for animal feedstuff ingredients for beef cattle (20 ug/kg). From previously mentioned data, it was clear that feedstaffs of animal and poultry in Egypt represented hazardous source of toxigenic fungi which harm animal and poultry health, decrease their production, and could be serious sources of human illness, so regular screening in animal and poultry feedstaffs in Egypt is a good practice in order to control and overcome their presence and dangers.
J.K.K.Nattraja College of Pharmacy, India
Keynote: Phytochemical Analysis and Neuroprotective activity of PEDALIUM MUREX LINN Leaves against Bacterial Cell Wall Content LIPOPOLYSACCHARIDE-Induced Endotoxemia
Time : 10:40-11:20
Neurodegenerative diseases (ND) are threatening worldwide. Huge number of behavioural changes are associated with ND such as depression, anxiety, memory loss, stress and so on. Effective drugs need to cure the ND from nature. In this present study, we had evaluated the phytochemical analysis and neuroprotective activity of Pedalium murex Linn (PM) leaves against bacterial cell wall content Lipopolysaccharide (LPS)-induced endotoxemia in rats. Two compounds were isolated from 90% v/v of ethanol extract of Pedalium murex Linn (EEPM) named as PM I, PM II. Spectral data of isolated compounds strongly suggested that PM I showed the structural similarities with 4´, 5, 7- trihydroxy flavone may be Apigenin and PM II showed the structural similarities with 3,5,7-Trihydroxy-2-(4-hydroxyphenyl)-4H-chromen-4-one which may have the presence of kaempferol. The data of our present study revealed that LPS significantly decreases the food, water intake and body mass which was recovered EEPM treated rats. EEPM attenuated or completely abolished the symptoms of depression and anxiety. Antioxidant enzymes includes SOD, CAT, GR, GPlevels were decreased in LPS-treated rats, which was recovered by EEPM treated rats. Histopathological results also support the neuroprotective effect of EEPM against LPS-induced neurodegeneration. We may conclude that EEPM may be a potential candidate for LPS-induced brain damage which may be attributed to the presence of potent antioxidants in EEPM
Sydney Sportsmed Specialists
Keynote: A phase 1 double-blind randomized controlled trial of allogeneic adipose derived mesenchymal stem cells (Progenza) for treatment of osteoarthritic knees
Time : 11:40-12:20
Dr Donald Kuah is an experienced Sports and Exercise Physician specialist and one of the founding practitioners at Sydney Sports Medicine Centre in Olympic Park. He has been the Chief Medical Officer to the Wests Tigers NRL team (2003-2013), is the current Chairman of the NRL Medical Advisory Panel and is on the Olympic Winter Institute of Australia medical panel. He was the NSW Institute of Sport Medical Director from 2000-2012, being responsible for the state’s top 700 elite athletes and remains involved with treating NSWIS athletes. Dr Kuah is involved in teaching at many levels and also heavily involved in clinical research. He has previously been the State Training Coordinator for the Australasian College of Sport and Exercise Medicine and continues to be a Clinical Training Supervisor and an Examiner for the College. His interest areas lie in treatment of tendon pathologies, osteoarthritis, hamstring origin pathologies and also in the area of regenerative medicine
Osteoarthritis (OA) is a debilitating condition with no known cure or disease-modifying treatments available. Stem cell therapies may have the potential to halt OA disease progression and repair and regenerate affected joints. Bone marrow (BM) and adipose-derived (AD) MSCs are being trialed for multiple diseases including OA but the majority of research has involved use of autologous cells (rather than allogeneic). A brief review of the literature will be presented. Two studies of knee OA patients receiving allogeneic BM-MSCs concluded MSCs were safe but varying efficacy results were reported. One study reported significant decreases in pain and encouraging MRI results in the MSC treated group. The second study observed no significant changes in objective and subjective pain measurements and no cartilage improvements by MRI. Allogeneic MSC safety has also been demonstrated in a cartilage defect study and in a study delivering the MSCs post partial meniscectomy. These studies reported improvements in pain and MRI measurements in patients that received MSCs.
The STEP (Safety, tolerability and Efficacy of Progenza) Trial was a first-in-human, Phase I, randomised, double-blind, placebo-controlled single ascending dose study of Progenza (PRG) for OA. PRG is composed of in vitro expanded AD-MSCs derived from human donor adipose tissue combined with cell culture supernatant, frozen in ready to inject vials.
The primary objective was to evaluate the safety and tolerability of PRG administered via a single intra-articular injection. Secondary objectives included investigating the effect of PRG on pain, function and joint structures in the study knee, quality of life and relevant serum and urine biomarkers. Twenty patients (40-65 years; Kellgren-Lawrence grade 1-3 knee OA and 35-90mm visual analogue scale pain score) were treated in two cohorts of 10 patients with a 12 month follow-up. Cohort 1: 3.9 million cells (n=8) or placebo (n=2) and cohort 2: 6.7 million cells (n=8) or placebo (n=2). All patients experienced at least 1 treatment emergent adverse event. Most were mild and unrelated to the Investigational Product (IP). No serious adverse events were reported, and no patients withdrew from the study due to an AE. VAS pain scores (Fig. 1) and WOMAC pain subscale scores significantly improved from baseline at all timepoints in the PRG groups (p < 0.05) whilst only a marginal non-statistically significant improvement was observed in the placebo group. Lateral tibial cartilage volume was preserved in the PRG 3.9M group whilst the placebo group showed a statistically significant cartilage loss.
PRG was safe and well tolerated when administered as a single intra-articular injection to patients with symptomatic knee OA. Improvements in knee structure outcomes demonstrates the potential for PRG to have a disease modifying effect in OA joints which warrants further investigation.